Dr. Garrett Harvey
About Dr. Garrett Harvey
Dr. Garrett Harvey serves as the VMD - Head of Medical Affairs at FidoCure®, a pioneering company in canine cancer care that integrates DNA testing and targeted therapies based on genetic markers.
VMD - Head of Medical Affairs at FidoCure®
Dr. Garrett Harvey holds the position of VMD - Head of Medical Affairs at FidoCure®. He plays a pivotal role in the company’s mission to bring targeted medicine used in human cancer care to canine cancer care. FidoCure® uses advanced DNA testing to identify genetic markers in canine cancer cases, enabling veterinarians to apply targeted therapies based on the individual genetic profile of each canine patient.
Treatment of Canine Cancer
At FidoCure®, Dr. Harvey works with a dedicated team that has treated thousands of dogs with various types of cancer. The service aims to address all forms of canine cancer, with significant experience in hemangiosarcoma, bladder cancer, and some rare canine cancers. By leveraging DNA insights, the team creates detailed reports with recommended targeted therapies, ensuring a tailored approach to each case.
Use of DNA Testing in Canine Cancer Care
Dr. Garrett Harvey is involved in the groundbreaking application of DNA testing to identify genetic markers in canine cancer. This process enables the creation of personalized reports that recommend targeted therapies, significantly enhancing the precision and effectiveness of cancer treatments for dogs. The DNA testing and bioinformatics pipeline help reduce sequencing costs and expand access to precision therapeutics in canine oncology.
Research and Development Contributions
As part of FidoCure®, Dr. Harvey contributes to research and development efforts that have amassed 1.7 billion data points on canine cancer. The company has published three peer-reviewed papers detailing the impact of their work on patient outcomes. This research is central to FidoCure®’s innovative approaches and helps push the boundaries of precision medicine in veterinary oncology.
Quality and Accessibility of Targeted Therapies
Dr. Harvey ensures that all targeted therapies facilitated by FidoCure® are sourced from licensed and Board of Pharmacy inspected facilities. The therapies are compounded from human-grade active pharmaceutical ingredients, emphasizing the quality and safety of the treatments provided. Through a network of partner compounding pharmacies, FidoCure® facilitates access to these crucial treatments, making advanced cancer care more accessible to canine patients.